HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.

Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks

Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.